Wang W - Search Results

1

Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera.

Mühlemann B, Wilks SH, Baracco L, Bekliz M, Carreño JM, Corman VM, Davis-Gardner ME, Dejnirattisai W, Diamond MS, Douek DC, Drosten C, Eckerle I, Edara VV, Ellis M, Fouchier RAM, Frieman M, Godbole S, Haagmans B, Halfmann PJ, Henry AR, Jones TC, Katzelnick LC, Kawaoka Y, Kimpel J, Krammer F, Lai L, Liu C, Lusvarghi S, Meyer B, Mongkolsapaya J, Montefiori DC, Mykytyn A, Netzl A, Pollett S, Rössler A, Screaton GR, Shen X, Sigal A, Simon V, Subramanian R, Supasa P, Suthar M, Türeli S, Wang W, Weiss CD, Smith DJ. Mühlemann B, et al. Among authors: wang w. bioRxiv [Preprint]. 2023 Sep 27:2023.09.27.559689. doi: 10.1101/2023.09.27.559689. bioRxiv. 2023. PMID: 37808679 Free PMC article. Preprint.

2

Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies.

Wang W, Butler EN, Veguilla V, Vassell R, Thomas JT, Moos M Jr, Ye Z, Hancock K, Weiss CD. Wang W, et al. J Virol Methods. 2008 Nov;153(2):111-9. doi: 10.1016/j.jviromet.2008.07.015. Epub 2008 Sep 4. J Virol Methods. 2008. PMID: 18722473

3

Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays.

Wang W, Xie H, Ye Z, Vassell R, Weiss CD. Wang W, et al. J Virol Methods. 2010 May;165(2):305-10. doi: 10.1016/j.jviromet.2010.02.009. Epub 2010 Feb 11. J Virol Methods. 2010. PMID: 20153374

4

A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity.

Wang W, Castelán-Vega JA, Jiménez-Alberto A, Vassell R, Ye Z, Weiss CD. Wang W, et al. Virology. 2010 Nov 25;407(2):374-80. doi: 10.1016/j.virol.2010.08.027. Epub 2010 Sep 24. Virology. 2010. PMID: 20869738 Free article.

5

Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2.

Wang W, Anderson CM, De Feo CJ, Zhuang M, Yang H, Vassell R, Xie H, Ye Z, Scott D, Weiss CD. Wang W, et al. PLoS Pathog. 2011 Jun;7(6):e1002081. doi: 10.1371/journal.ppat.1002081. Epub 2011 Jun 9. PLoS Pathog. 2011. PMID: 21695241 Free PMC article.

6

Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Wang W, De Feo CJ, Zhuang M, Vassell R, Weiss CD. Wang W, et al. J Virol. 2011 Dec;85(24):12929-38. doi: 10.1128/JVI.05391-11. Epub 2011 Oct 12. J Virol. 2011. PMID: 21994458 Free PMC article.

7

Comparison of hemagglutination inhibition and hemagglutinin pseudovirus neutralization titres in relation to protection against influenza in a mouse model.

Huang Y, Lin Z, Wang W, Weiss C, Xie H, Forshee RA. Huang Y, et al. Among authors: wang w. Lett Appl Microbiol. 2021 Sep;73(3):294-299. doi: 10.1111/lam.13513. Epub 2021 Jun 11. Lett Appl Microbiol. 2021. PMID: 34028058

8

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster.

Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, Colombo CJ, Mody R, Ewers EC, Lalani T, Ganesan A, Goguet E, Hollis-Perry M, Coggins SA, Simons MP, Katzelnick LC, Wang G, Tribble DR, Bentley L, Eakin AE, Broder CC, Erlandson KJ, Laing ED, Burgess TH, Mitre E, Weiss CD. Lusvarghi S, et al. Among authors: wang w, wang g, wang r. bioRxiv [Preprint]. 2021 Dec 28:2021.12.22.473880. doi: 10.1101/2021.12.22.473880. bioRxiv. 2021. PMID: 34981057 Free PMC article. Updated. Preprint.

9

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies.

Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, Colombo CJ, Mody R, Ewers EC, Lalani T, Ganesan A, Goguet E, Hollis-Perry M, Coggins SA, Simons MP, Katzelnick LC, Wang G, Tribble DR, Bentley L, Eakin AE, Broder CC, Erlandson KJ, Laing ED, Burgess TH, Mitre E, Weiss CD. Lusvarghi S, et al. Among authors: wang w, wang g, wang r. Sci Transl Med. 2022 May 18;14(645):eabn8543. doi: 10.1126/scitranslmed.abn8543. Epub 2022 May 18. Sci Transl Med. 2022. PMID: 35380448 Free PMC article.

10

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.

Neerukonda SN, Wang R, Vassell R, Baha H, Lusvarghi S, Liu S, Wang T, Weiss CD, Wang W. Neerukonda SN, et al. Among authors: wang w, wang t, wang r. J Virol. 2022 Sep 14;96(17):e0114022. doi: 10.1128/jvi.01140-22. Epub 2022 Aug 24. J Virol. 2022. PMID: 36000843 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

82,425 results

Search Page